Literature DB >> 18287760

Bioluminescent imaging of bacterial biofilm infections in vivo.

Jagath L Kadurugamuwa1, Kevin P Francis.   

Abstract

Whole body biophotonic imaging (BPI) is a technique that has contributed significantly to the way researchers study bacterial pathogens and develop pre-clinical treatments to combat their ensuing infections in vivo. Not only does this approach allow disease profiles and drug efficacy studies to be conducted non-destructively in live animals over the entire course of the disease, but in many cases, it enables investigators to observe disease profiles that could otherwise easily be missed using conventional methodologies. The principles of this technique are that bacterial pathogens engineered to express bioluminescence (visible light) can be readily monitored from outside of the living animal using specialized low-light imaging equipment, enabling their movement, expansion and treatment to be seen completely non-invasively. Moreover, because the same group of animals can be imaged at each time-point throughout the study, the overall number of animals used is dramatically reduced, saving lives, time, and money. Also, as each animal acts as its own control over time, the issues associated with animal-to-animal variation are circumvented, thus improving the quality of the biostatistical data generated. The ability to monitor infections in vivo in a longitudinal fashion is especially appealing to assess chronic infections such as those involving implanted devices. Typically, bacteria grow as biofilms on these foreign bodies and are reputably difficult to monitor with conventional methods. Because of the non-destructive and non-invasive nature of BPI, the procedure can be performed repeatedly in the same animal, allowing the biofilm to be studied in situ without detachment or disturbance. This ability not only allows unique patterns of disease relapse to be seen following termination of antibiotic therapy but also in vivo resistance development during prolonged treatment, both of which are common occurrences with device-related infections. This chapter describes the bioluminescent engineering of both Gram-positive and Gram-negative bacteria and overviews their use in device-associated infections in several anatomical sites in a variety of animal models.

Entities:  

Mesh:

Year:  2008        PMID: 18287760     DOI: 10.1007/978-1-60327-032-8_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

Review 1.  Options and Limitations in Clinical Investigation of Bacterial Biofilms.

Authors:  Maria Magana; Christina Sereti; Anastasios Ioannidis; Courtney A Mitchell; Anthony R Ball; Emmanouil Magiorkinis; Stylianos Chatzipanagiotou; Michael R Hamblin; Maria Hadjifrangiskou; George P Tegos
Journal:  Clin Microbiol Rev       Date:  2018-04-04       Impact factor: 26.132

Review 2.  Phenazine Antibiotic-Inspired Discovery of Bacterial Biofilm-Eradicating Agents.

Authors:  Robert W Huigens; Yasmeen Abouelhassan; Hongfen Yang
Journal:  Chembiochem       Date:  2019-10-02       Impact factor: 3.164

3.  Maggot excretions inhibit biofilm formation on biomaterials.

Authors:  Gwendolyn Cazander; Mariëlle C van de Veerdonk; Christina M J E Vandenbroucke-Grauls; Marco W J Schreurs; Gerrolt N Jukema
Journal:  Clin Orthop Relat Res       Date:  2010-03-23       Impact factor: 4.176

Review 4.  Bioluminescence imaging of reporter mice for studies of infection and inflammation.

Authors:  Kathryn E Luker; Gary D Luker
Journal:  Antiviral Res       Date:  2010-04       Impact factor: 5.970

5.  Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.

Authors:  Meru Sheel; Manisha Pandey; Michael F Good; Michael R Batzloff
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

6.  The influence of maggot excretions on PAO1 biofilm formation on different biomaterials.

Authors:  Gwendolyn Cazander; Kiril E B van Veen; Lee H Bouwman; Alexandra T Bernards; Gerrolt N Jukema
Journal:  Clin Orthop Relat Res       Date:  2008-10-16       Impact factor: 4.176

7.  Efficacy of enrofloxacin in a mouse model of sepsis.

Authors:  Andrea R Slate; Sheila Bandyopadhyay; Kevin P Francis; Mark G Papich; Brian Karolewski; Eldad A Hod; Kevin A Prestia
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

8.  A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections.

Authors:  Ashwini Chauhan; David Lebeaux; Benoit Decante; Irene Kriegel; Marie-Christine Escande; Jean-Marc Ghigo; Christophe Beloin
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

9.  Impact of Anesthesia Protocols on In Vivo Bioluminescent Bacteria Imaging Results.

Authors:  Thomas Chuzel; Violette Sanchez; Marc Vandamme; Stéphane Martin; Odile Flety; Aurélie Pager; Christophe Chabanel; Luc Magnier; Marie Foskolos; Océane Petit; Bachra Rokbi; Emmanuel Chereul
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

10.  Tn5/7-lux: a versatile tool for the identification and capture of promoters in gram-negative bacteria.

Authors:  Steven T Bruckbauer; Brian H Kvitko; RoxAnn R Karkhoff-Schweizer; Herbert P Schweizer
Journal:  BMC Microbiol       Date:  2015-02-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.